RESUMEN
Traditional medicinal plants are an important source of active compounds with potential antimutagenic activity. Polyscias filicifolia Bailey (Araliaceae) is a South Asian traditional herb used as an adaptogenic and cardiac drug. Extracts of P. filicifolia contain a wide range of biologically active compounds like phenolic acids and triterpenoid saponins. In the present study. antigenotoxic potential of three naturally occurring phenolic acids and extracts of P. filicifolia growing in vitro with the addition of elicitors was evaluated against direct (4-nitroquinoline-N-oxide (4NQO) and mitomycin C (MMC)) and indirect mutagens (2-aminoanthracene (2AA)). The evaluation was made using a bacterial umu-test. Moreover, the ability to prevent photogenotoxicity induced by chlorpromazine (CPZ) under UVA irradiation was measured. The phytochemical profiling of examined extracts revealed the presence of numerous compounds with the prevelance of chlorogenic, caffeic, and ferulic acid derivatives; however, saponin fractions were also determined. The antioxidant potential of extracts strictly correlated with their composition. The tested extracts exhibited high antigenotoxic activity if the assay was performed with 2AA and metabolic activation. Moreover, the extracts slightly decreased the MMC-induced genotoxicity. However, an increase of the genotoxic effect was observed in the assay performed with 4NQO. In addition, photo-antigenotoxic activity was observed. In our study, phenolic acids exhibited lower activity than the extracts.
Asunto(s)
Antimutagênicos/farmacología , Antioxidantes/farmacología , Araliaceae/química , Daño del ADN , Extractos Vegetales/farmacología , Brotes de la Planta/química , Animales , Antimutagênicos/química , Antioxidantes/química , Clorpromazina/efectos adversos , Clorpromazina/farmacología , Masculino , Mitomicina/efectos adversos , Mitomicina/farmacología , Extractos Vegetales/química , Ratas , Ratas Sprague-DawleyRESUMEN
BACKGROUND: Cannabis has a long history of medicinal use. Cannabis-based medications (cannabinoids) are based on its active element, delta-9-tetrahydrocannabinol (THC), and have been approved for medical purposes. Cannabinoids may be a useful therapeutic option for people with chemotherapy-induced nausea and vomiting that respond poorly to commonly used anti-emetic agents (anti-sickness drugs). However, unpleasant adverse effects may limit their widespread use. OBJECTIVES: To evaluate the effectiveness and tolerability of cannabis-based medications for chemotherapy-induced nausea and vomiting in adults with cancer. SEARCH METHODS: We identified studies by searching the following electronic databases: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, PsycINFO and LILACS from inception to January 2015. We also searched reference lists of reviews and included studies. We did not restrict the search by language of publication. SELECTION CRITERIA: We included randomised controlled trials (RCTs) that compared a cannabis-based medication with either placebo or with a conventional anti-emetic in adults receiving chemotherapy. DATA COLLECTION AND ANALYSIS: At least two review authors independently conducted eligibility and risk of bias assessment, and extracted data. We grouped studies based on control groups for meta-analyses conducted using random effects. We expressed efficacy and tolerability outcomes as risk ratio (RR) with 95% confidence intervals (CI). MAIN RESULTS: We included 23 RCTs. Most were of cross-over design, on adults undergoing a variety of chemotherapeutic regimens ranging from moderate to high emetic potential for a variety of cancers. The majority of the studies were at risk of bias due to either lack of allocation concealment or attrition. Trials were conducted between 1975 and 1991. No trials involved comparison with newer anti-emetic drugs such as ondansetron. Comparison with placebo People had more chance of reporting complete absence of vomiting (3 trials; 168 participants; RR 5.7; 95% CI 2.6 to 12.6; low quality evidence) and complete absence of nausea and vomiting (3 trials; 288 participants; RR 2.9; 95% CI 1.8 to 4.7; moderate quality evidence) when they received cannabinoids compared with placebo. The percentage of variability in effect estimates that was due to heterogeneity rather than chance was not important (I(2) = 0% in both analyses).People had more chance of withdrawing due to an adverse event (2 trials; 276 participants; RR 6.9; 95% CI 1.96 to 24; I(2) = 0%; very low quality evidence) and less chance of withdrawing due to lack of efficacy when they received cannabinoids, compared with placebo (1 trial; 228 participants; RR 0.05; 95% CI 0.0 to 0.89; low quality evidence). In addition, people had more chance of 'feeling high' when they received cannabinoids compared with placebo (3 trials; 137 participants; RR 31; 95% CI 6.4 to 152; I(2) = 0%).People reported a preference for cannabinoids rather than placebo (2 trials; 256 participants; RR 4.8; 95% CI 1.7 to 13; low quality evidence). Comparison with other anti-emetics There was no evidence of a difference between cannabinoids and prochlorperazine in the proportion of participants reporting no nausea (5 trials; 258 participants; RR 1.5; 95% CI 0.67 to 3.2; I(2) = 63%; low quality evidence), no vomiting (4 trials; 209 participants; RR 1.11; 95% CI 0.86 to 1.44; I(2) = 0%; moderate quality evidence), or complete absence of nausea and vomiting (4 trials; 414 participants; RR 2.0; 95% CI 0.74 to 5.4; I(2) = 60%; low quality evidence). Sensitivity analysis where the two parallel group trials were pooled after removal of the five cross-over trials showed no difference (RR 1.1; 95% CI 0.70 to 1.7) with no heterogeneity (I(2) = 0%).People had more chance of withdrawing due to an adverse event (5 trials; 664 participants; RR 3.9; 95% CI 1.3 to 12; I(2) = 17%; low quality evidence), due to lack of efficacy (1 trial; 42 participants; RR 3.5; 95% CI 1.4 to 8.9; very low quality evidence) and for any reason (1 trial; 42 participants; RR 3.5; 95% CI 1.4 to 8.9; low quality evidence) when they received cannabinoids compared with prochlorperazine.People had more chance of reporting dizziness (7 trials; 675 participants; RR 2.4; 95% CI 1.8 to 3.1; I(2) = 12%), dysphoria (3 trials; 192 participants; RR 7.2; 95% CI 1.3 to 39; I(2) = 0%), euphoria (2 trials; 280 participants; RR 18; 95% CI 2.4 to 133; I(2) = 0%), 'feeling high' (4 trials; 389 participants; RR 6.2; 95% CI 3.5 to 11; I(2) = 0%) and sedation (8 trials; 947 participants; RR 1.4; 95% CI 1.2 to 1.8; I(2) = 31%), with significantly more participants reporting the incidence of these adverse events with cannabinoids compared with prochlorperazine.People reported a preference for cannabinoids rather than prochlorperazine (7 trials; 695 participants; RR 3.3; 95% CI 2.2 to 4.8; I(2) = 51%; low quality evidence).In comparisons with metoclopramide, domperidone and chlorpromazine, there was weaker evidence, based on fewer trials and participants, for higher incidence of dizziness with cannabinoids.Two trials with 141 participants compared an anti-emetic drug alone with a cannabinoid added to the anti-emetic drug. There was no evidence of differences between groups; however, the majority of the analyses were based on one small trial with few events. Quality of the evidence The trials were generally at low to moderate risk of bias in terms of how they were designed and do not reflect current chemotherapy and anti-emetic treatment regimens. Furthermore, the quality of evidence arising from meta-analyses was graded as low for the majority of the outcomes analysed, indicating that we are not very confident in our ability to say how well the medications worked. Further research is likely to have an important impact on the results. AUTHORS' CONCLUSIONS: Cannabis-based medications may be useful for treating refractory chemotherapy-induced nausea and vomiting. However, methodological limitations of the trials limit our conclusions and further research reflecting current chemotherapy regimens and newer anti-emetic drugs is likely to modify these conclusions.
Asunto(s)
Antieméticos/uso terapéutico , Cannabinoides/uso terapéutico , Náusea/tratamiento farmacológico , Neoplasias/tratamiento farmacológico , Vómitos/tratamiento farmacológico , Adulto , Antieméticos/efectos adversos , Antineoplásicos/efectos adversos , Cannabinoides/efectos adversos , Clorpromazina/efectos adversos , Clorpromazina/uso terapéutico , Mareo/inducido químicamente , Domperidona/efectos adversos , Domperidona/uso terapéutico , Euforia , Humanos , Metoclopramida/efectos adversos , Metoclopramida/uso terapéutico , Náusea/inducido químicamente , Proclorperazina/efectos adversos , Proclorperazina/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , Vómitos/inducido químicamenteRESUMEN
BACKGROUNDS: Yin-Chen-Hao-Tang (YCHT), a commonly used as a traditional chinese medicine for liver disease. Several studies indicated that YCHT may improving hepatic triglyceride metabolism and anti-apoptotic response as well as decreasing oxidative stress .However, little is known about the role of YCHT in chlorpromazine (CPZ) -induced chlolestatic liver injury. Therefore, we aimed to facilitate the understanding of the pathogenesis of cholestatic liver injury and evaluate the effect of Yin-Chen-Hao-Tang (YCHT) on chlorpromazine (CPZ)-induced cholestatic liver injury in rats based on the change of bile acids (BAs) and free fatty acids (FFAs) alone with the biochemical indicators and histological examination. METHODS: We conducted an experiment on CPZ-induced cholestatic liver injury in Wistar rats with and without YCHT for nine consecutive days. Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), total bilirubin (TBIL), total cholesterol (TC), triglycerides (TG), low density lipoprotein-cholesterol (LDL-C) were measured to evaluate the protective effect of YCHT against chlorpromazine (CPZ)-induced cholestatic liver injury. Histopathology of the liver tissue showed that pathological injuries were relieved after YCHT pretreatment. In addition, ultra-performance lipid chromatography coupled with quadrupole mass spectrometry (UPLC-MS) and gas chromatography coupled with mass spectrometry (GC-MS) was applied to determine the content of bile acids, free fatty acids, respectively. RESULTS: Obtained data showed that YCHT attenuated the effect of CPZ-induced cholestatic liver injury, which was manifested by the serum biochemical parameters and histopathology of the liver tissue. YCHT regulated the lipid levels as indicated by the reversed serum levels of TC, TG, and LDL-C. YCHT also regulated the disorder of BA and FFA metabolism by CPZ induction. CONCLUSIONS: Results indicated that YCHT exerted a protective effect on CPZ-induced cholestasis liver injury. The variance of BA and FFA concentrations can be used to evaluate the cholestatic liver injury caused by CPZ and the hepatoprotective effect of YCHT.
Asunto(s)
Ácidos y Sales Biliares/metabolismo , Enfermedad Hepática Inducida por Sustancias y Drogas/prevención & control , Clorpromazina/efectos adversos , Colestasis/prevención & control , Medicamentos Herbarios Chinos/uso terapéutico , Ácidos Grasos no Esterificados/metabolismo , Hígado/efectos de los fármacos , Animales , Artemisia , Enfermedad Hepática Inducida por Sustancias y Drogas/metabolismo , Colestasis/inducido químicamente , Colestasis/metabolismo , Medicamentos Herbarios Chinos/farmacología , Gardenia , Hígado/metabolismo , Hígado/patología , Masculino , Espectrometría de Masas , Medicina Tradicional China , Estrés Oxidativo/efectos de los fármacos , Fitoterapia , Ratas , Ratas Wistar , RheumRESUMEN
Chlorpromazine is used in the treatment of schizophrenia and psychotic disorders and belongs to phenothiazine class of neuroleptic drugs. It shows severe side effects such as extrapyramidal symptoms as well as ocular and skin disorders, but the mechanism is still not fully established. The aim of this study was to examine the effect of chlorpromazine on cell viability, melanogenesis and antioxidant defense system in normal human melanocytes. It has been demonstrated that chlorpromazine induces concentration dependent loss in cell viability. The value of EC(50) was calculated to be 2.53 µM. Chlorpromazine in lower concentrations (0.0001, 0.001 and 0.01 µM) increased the melanin and microphthalmia-associated transcription factor (MITF) content and tyrosinase activity, while changes of antioxidant enzymes activity were not observed. It suggests that long-term chlorpromazine therapy, even with low drug doses, may lead to hyperpigmentation disorders in skin and/or eye. The use of the analyzed drug in higher concentrations (0.1 and 1.0 µM) caused significant alterations of antioxidant enzymes activity in normal melanocytes, what may explain a potential role of chlorpromazine in the depletion of cellular antioxidant status leading to other adverse effects associated with the high-dose and/or long-term therapy.
Asunto(s)
Antipsicóticos/efectos adversos , Clorpromazina/efectos adversos , Melaninas/biosíntesis , Melanocitos/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Catalasa/metabolismo , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Relación Dosis-Respuesta a Droga , Glutatión Peroxidasa/metabolismo , Humanos , Peróxido de Hidrógeno/análisis , Melaninas/análisis , Melanocitos/química , Melanocitos/metabolismo , Melanocitos/fisiología , Monofenol Monooxigenasa/metabolismo , Superóxido Dismutasa/metabolismoAsunto(s)
Colestasis/inducido químicamente , Anabolizantes/efectos adversos , Antibacterianos/efectos adversos , Antiinflamatorios no Esteroideos/efectos adversos , Anticonvulsivantes/efectos adversos , Antidepresivos/efectos adversos , Antineoplásicos/efectos adversos , Clorpromazina/efectos adversos , Colestasis/diagnóstico , Colestasis/terapia , Humanos , Inmunosupresores/efectos adversos , Medicina Tradicional China/efectos adversosAsunto(s)
Anfetamina/efectos adversos , Anticonvulsivantes/efectos adversos , Regulación de la Temperatura Corporal/efectos de los fármacos , Clorpromazina/efectos adversos , Dextrometorfano/efectos adversos , Fiebre/inducido químicamente , Antagonistas de los Receptores Histamínicos/efectos adversos , Antiinflamatorios no Esteroideos , Regulación de la Temperatura Corporal/fisiología , Contraindicaciones , Homeostasis , Humanos , Hidralazina/efectos adversos , Hipotálamo/fisiología , Isoniazida/efectos adversos , Lupus Eritematoso Sistémico/inducido químicamente , Sistema Nervioso Simpático/fisiologíaAsunto(s)
Antibacterianos/efectos adversos , Antipsicóticos/efectos adversos , Clorpromazina/efectos adversos , Colestasis/inducido químicamente , Antiinflamatorios no Esteroideos/efectos adversos , Anticonvulsivantes/efectos adversos , Antineoplásicos/efectos adversos , Colestasis/diagnóstico , Colestasis/terapia , Medicamentos Herbarios Chinos/efectos adversos , Eritromicina/efectos adversos , Humanos , Inmunosupresores/efectos adversos , Penicilinas/efectos adversos , Sulfametoxazol/efectos adversos , Congéneres de la Testosterona/efectos adversos , Trimetoprim/efectos adversosRESUMEN
OBJECTIVE: The authors performed a longitudinal study of the effects on thalamic volume of switching from typical to atypical antipsychotic medications. METHOD: Magnetic resonance imaging scans were acquired from 10 subjects with chronic schizophrenia taking typical antipsychotics and 20 healthy volunteers. Subjects with schizophrenia were switched to olanzapine; both groups were rescanned. RESULTS: At baseline, thalamic volumes in subjects with chronic schizophrenia were 5.8% greater than those of healthy volunteers. At follow-up, there was no significant difference between groups. Additional analysis revealed a significant positive correlation between baseline thalamic volume and dosage of typical antipsychotic medication. Higher dosages at baseline were correlated with larger reductions in volume after the switch to olanzapine. CONCLUSIONS: Antipsychotic medication effects may be a factor in the wide range of thalamic volume differences reported between subjects with schizophrenia and healthy volunteers.
Asunto(s)
Antipsicóticos/efectos adversos , Esquizofrenia/tratamiento farmacológico , Esquizofrenia/patología , Tálamo/patología , Adulto , Antipsicóticos/uso terapéutico , Atrofia , Benzodiazepinas/efectos adversos , Benzodiazepinas/uso terapéutico , Clorpromazina/efectos adversos , Clorpromazina/uso terapéutico , Enfermedad Crónica , Femenino , Estudios de Seguimiento , Humanos , Hipertrofia , Estudios Longitudinales , Imagen por Resonancia Magnética , Masculino , Olanzapina , Tálamo/efectos de los fármacos , Equivalencia TerapéuticaRESUMEN
In view of the evidence that cognitive deficits in schizophrenia are critically important for long-term outcome, it is essential to establish the effects that the various antipsychotic compounds have on cognition, particularly second-generation drugs. This parallel group, placebo-controlled study aimed to compare the effects in healthy volunteers (n = 128) of acute doses of the atypical antipsychotics amisulpride (300 mg) and risperidone (3 mg) to those of chlorpromazine (100 mg) on tests thought relevant to the schizophrenic process: auditory and visual latent inhibition, prepulse inhibition of the acoustic startle response, executive function and eye movements. The drugs tested were not found to affect auditory latent inhibition, prepulse inhibition or executive functioning as measured by the Cambridge Neuropsychological Test Battery and the FAS test of verbal fluency. However, risperidone disrupted and amisulpride showed a trend to disrupt visual latent inhibition. Although amisulpride did not affect eye movements, both risperidone and chlorpromazine decreased peak saccadic velocity and increased antisaccade error rates, which, in the risperidone group, correlated with drug-induced akathisia. It was concluded that single doses of these drugs appear to have little effect on cognition, but may affect eye movement parameters in accordance with the amount of sedation and akathisia they produce. The effect risperidone had on latent inhibition is likely to relate to its serotonergic properties. Furthermore, as the trend for disrupted visual latent inhibition following amisulpride was similar in nature to that which would be expected with amphetamine, it was concluded that its behaviour in this model is consistent with its preferential presynaptic dopamine antagonistic activity in low dose and its efficacy in the negative symptoms of schizophrenia.
Asunto(s)
Estimulación Acústica , Clorpromazina/efectos adversos , Movimientos Oculares/efectos de los fármacos , Risperidona/efectos adversos , Sulpirida/análogos & derivados , Sulpirida/efectos adversos , Estimulación Acústica/efectos adversos , Administración Oral , Adulto , Acatisia Inducida por Medicamentos/etiología , Amisulprida , Presión Sanguínea/efectos de los fármacos , Presión Sanguínea/fisiología , Clorpromazina/administración & dosificación , Clorpromazina/farmacocinética , Ensayos Clínicos Controlados como Asunto , Demografía , Método Doble Ciego , Movimientos Oculares/fisiología , Humanos , Masculino , Pruebas Neuropsicológicas , Estimulación Luminosa , Solución de Problemas/efectos de los fármacos , Solución de Problemas/fisiología , Tiempo de Reacción/efectos de los fármacos , Reflejo de Sobresalto/efectos de los fármacos , Reflejo de Sobresalto/fisiología , Risperidona/administración & dosificación , Risperidona/farmacocinética , Percepción Espacial/efectos de los fármacos , Percepción Espacial/fisiología , Sulpirida/administración & dosificación , Conducta Verbal/efectos de los fármacos , Conducta Verbal/fisiologíaRESUMEN
RATIONALE: Quetiapine, an atypical neuroleptic, has beneficial antipsychotic effects in schizophrenic patients, but with a lower incidence of extrapyramidal symptoms (EPS) compared with typical antipsychotics. While typical antipsychotics are often switched to atypical agents when adverse effects become limiting, there is little preclinical information to support this strategy, both in terms of efficacy and side effects. OBJECTIVES: The antipsychotic effects and EPS during concomitant administration of quetiapine with haloperidol, a typical antipsychotic agent, were evaluated in mice and compared with chlorpromazine and risperidone. METHODS: We first investigated the antipsychotic effects and EPS liability of quetiapine, risperidone, chlorpromazine, and haloperidol when administered alone to select optimal doses for subsequent combination studies. The second study was designed to evaluate the antipsychotic efficacy and EPS profile of concomitant administration of quetiapine, risperidone, or chlorpromazine with haloperidol. Antipsychotic effects were evaluated with the methamphetamine-induced hyperlocomotion test, and EPS liability was evaluated in a catalepsy-induction model. RESULTS: Quetiapine, risperidone, chlorpromazine, and haloperidol dose-dependently reduced methamphetamine-induced hyperlocomotion, with ED50 values of 5.6, 0.020, 1.8, 0.035 mg/kg, respectively. In the catalepsy test, quetiapine only weakly induced catalepsy at the highest dose of 100 mg/kg, whereas risperidone, chlorpromazine, and haloperidol dose-dependently induced catalepsy with ED50 values of 0.25, 4.6, and 0.10 mg/kg, respectively. While the combination of quetiapine (6 mg/kg) and haloperidol (0.04 mg/kg) significantly reduced methamphetamine-induced hyperlocomotion in comparison with haloperidol alone, quetiapine (10, 32 mg/kg) plus haloperidol did not potentiate the cataleptogenic activity of haloperidol. In contrast, risperidone (0.1, 0.32 mg/kg) or chlorpromazine (3.2 mg/kg) significantly augmented catalepsy induced by haloperidol. Catalepsy induced by co-administration of quetiapine (10 mg/kg) and haloperidol (0.1 mg/kg) was significantly potentiated by WAY100635, a 5-HT1A antagonist, and catalepsy induced by co-administration of risperidone (0.1 mg/kg) and haloperidol (0.1 mg/kg) was significantly antagonized by 8-OH-DPAT, a 5-HT1A agonist. CONCLUSION: The present study demonstrated that the combined administration of quetiapine with haloperidol did not aggravate EPS, possibly because of its affinity for 5-HT1A receptors. This finding may have the clinical implication that quetiapine could provide a successful regimen in switching from typical antipsychotic agents in the symptom management of schizophrenia, or even in adjunctive therapy with other antipsychotic agents.
Asunto(s)
Antipsicóticos/uso terapéutico , Enfermedades de los Ganglios Basales/inducido químicamente , Clorpromazina/uso terapéutico , Dibenzotiazepinas/uso terapéutico , Modelos Animales de Enfermedad , Haloperidol/uso terapéutico , Risperidona/uso terapéutico , 8-Hidroxi-2-(di-n-propilamino)tetralin/administración & dosificación , 8-Hidroxi-2-(di-n-propilamino)tetralin/farmacocinética , Administración Oral , Animales , Antipsicóticos/efectos adversos , Enfermedades de los Ganglios Basales/complicaciones , Enfermedades de los Ganglios Basales/fisiopatología , Catalepsia/inducido químicamente , Catalepsia/tratamiento farmacológico , Catalepsia/prevención & control , Clorpromazina/administración & dosificación , Clorpromazina/efectos adversos , Dibenzotiazepinas/administración & dosificación , Dibenzotiazepinas/efectos adversos , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Evaluación Preclínica de Medicamentos/métodos , Sinergismo Farmacológico , Quimioterapia Combinada , Haloperidol/administración & dosificación , Haloperidol/efectos adversos , Hipercinesia/inducido químicamente , Hipercinesia/prevención & control , Inyecciones Intraperitoneales , Masculino , Metanfetamina/administración & dosificación , Metanfetamina/efectos adversos , Metanfetamina/antagonistas & inhibidores , Ratones , Piperazinas/administración & dosificación , Piperazinas/farmacocinética , Piridinas/administración & dosificación , Piridinas/farmacocinética , Fumarato de Quetiapina , Receptor de Serotonina 5-HT1A/administración & dosificación , Risperidona/administración & dosificación , Risperidona/efectos adversos , Esquizofrenia/inducido químicamente , Esquizofrenia/complicaciones , Esquizofrenia/tratamiento farmacológico , Agonistas del Receptor de Serotonina 5-HT1 , Antagonistas del Receptor de Serotonina 5-HT1RESUMEN
Se comunica una paciente de 44 años de edad que presentaba lesiones kaposiformes profusas, manifestación cutánea infrecuente del síndrome antifosfolípido. Se describen las características clínicas, los hallazgos de laboratorio, así como el tratamiento de esta enfermedad multisistémica (AU)
Asunto(s)
Humanos , Adulto , Femenino , Síndrome Antifosfolípido/diagnóstico , Anticuerpos Antifosfolípidos , Trombosis/etiología , Enfermedad Medicamentosa , Síndrome Antifosfolípido/tratamiento farmacológico , Síndrome Antifosfolípido/complicaciones , Fenotiazinas/efectos adversos , Procainamida/efectos adversos , Clorpromazina/efectos adversos , Hidralazina/efectos adversos , Clorotiazida/efectos adversos , Etosuximida/efectos adversos , Fenitoína/efectos adversos , Penicilinas/efectos adversos , Quinina/efectos adversos , Quinidina/efectos adversos , Anticonceptivos Orales/efectos adversos , Anticonceptivos Hormonales Orales/efectos adversos , Anticonceptivos Sintéticos Orales/efectos adversos , Estreptomicina/efectos adversos , Pirimetamina/efectos adversos , Interferón-alfa/efectos adversos , Bloqueadores de los Canales de Calcio/efectos adversosAsunto(s)
Metabolismo Energético/fisiología , Hidrocortisona/sangre , Hipotálamo/metabolismo , Esquizofrenia/sangre , Antipsicóticos/efectos adversos , Antipsicóticos/uso terapéutico , Clorpromazina/efectos adversos , Clorpromazina/uso terapéutico , Glucosa/metabolismo , Humanos , Esquizofrenia/tratamiento farmacológico , Sulpirida/efectos adversos , Sulpirida/uso terapéutico , Tomografía Computarizada de EmisiónRESUMEN
Hypotension induced by nifedipine and chlorpromazine is discussed, together with the role of noradrenaline in the correction of this problem, which was resistant to other forms of therapy.
Asunto(s)
Hipotensión/tratamiento farmacológico , Norepinefrina/uso terapéutico , Clorpromazina/efectos adversos , Humanos , Hipotensión/inducido químicamente , Masculino , Persona de Mediana Edad , Nifedipino/efectos adversosRESUMEN
Nineteen Chinese patients receiving chemotherapy for advanced cancer were studied for chemotherapy-induced acute nausea and vomiting. The chemotherapy consisted of cisplatinum 100 mg/m2 i.v. infusion over 4 h on day 1 and 5-fluorouracil (5-FU) 1000 mg/m2 120-h continuous infusion from day 2 to day 6, repeated every 3 weeks. At the first course of chemotherapy the patients were randomized to receive either low-dose metoclopramide and chlorpromazine or high-dose metoclopramide, and then crossed over for the second course. In the high-dose metoclopramide group there was a suggestion of an earlier onset of emesis, with slightly more frequent retching and vomiting and less food consumed. However, the duration of emesis was shorter in the high-dose group. These differences were not statistically significant. There were no major side effects. Mild salutary drowsiness was noticed in patients receiving low-dose metoclopramide and chlorpromazine. This trial suggests that, in the dosage, route and schedule described, high-dose metoclopramide is no more effective than low-dose metoclopramide together with chlorpromazine in preventing cisplatinum-induced nausea and vomiting. The low-dose scheme is more economic and suitable for patients with advanced cancer.
Asunto(s)
Clorpromazina/administración & dosificación , Cisplatino/efectos adversos , Fluorouracilo/administración & dosificación , Metoclopramida/administración & dosificación , Náusea/prevención & control , Vómitos/prevención & control , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Clorpromazina/efectos adversos , Cisplatino/administración & dosificación , Ensayos Clínicos como Asunto , Quimioterapia Combinada , Ingestión de Alimentos , Femenino , Hong Kong , Humanos , Masculino , Metoclopramida/efectos adversos , Persona de Mediana Edad , Náusea/inducido químicamente , Neoplasias/tratamiento farmacológico , Distribución Aleatoria , Factores de Tiempo , Vómitos/inducido químicamenteRESUMEN
The photosensitizing potential of chemicals known to produce photosensitivity in humans was compared to chemicals not considered to be photosensitizers in an in vitro assay. The assay involved exposure of human lymphoid cells to UVA (320-400 nm), and in some cases UVB (280-320 nm) radiation, in the presence of the chemicals and the assessement of phototoxicity as measured by the incorporation of 3[H]-thymidine into nuclear DNA. All known photosensitizers tested were found to be phototoxic, while the nonphotosensitizing agents, with the exception of retinoic acid, were not phototoxic. Peripheral blood mononuclear cells were compared to a T lymphoblastoid cell line as target cells; the latter were superior in terms of convenience, cost and reproducibility of results. This test system has potential as a predictive assay for detecting additional phototoxic chemicals.
Asunto(s)
Evaluación Preclínica de Medicamentos/métodos , Linfocitos/efectos de los fármacos , Linfocitos/efectos de la radiación , Trastornos por Fotosensibilidad/etiología , Rayos Ultravioleta/efectos adversos , Células Cultivadas , Clorpromazina/efectos adversos , Humanos , Linfocitos/metabolismo , Metoxaleno/efectos adversos , Timidina/metabolismoRESUMEN
PIP: This article catalogs the nutritional deficiencies inadvertently introduced by certain treatment regimens. Specifically, the iatrogenic effects on nutrition of surgery, hemodialysis, irradiation, and drugs are reviewed. Nutritional problems are particularly frequent consequences of surgery on the gastrointestinal tract. Gastric surgery can lead to deficiencies of vitamin B12, folate, iron, and thiamine, as well as to metabolic bone disease. The benefits of small bowel bypass are limited by the potentially severe nutritional consequences of this procedure. Following bypass surgery, patients should be monitored for signs of possible nutritional probems such as weight loss, neuropathy, cardiac arrhythmias, loss of stamina, or changes in mental status. Minimal laboratory tests should include hematologic evaluation, B12, folate, iron, albumin, calcium, phosphorus, alkaline phosphatase, transaminases, sodium, potassium, chloride, and carbon dioxide levels. Roentgenologic examination of the bone should also be obtained. Loss of bone substance is a major consequence of many forms of treatment, and dietary supplementation with calcium is warranted. Patients undergoing hemodialysis have shown carnitine and choline deficiencies, potassium depletion, and hypovitaminosis, as well as osteomalacia. Chronic drug use may alter intake, synthesis, absorption, transport, storage, metabolism, or excretion of nutrients. Patients vary markedly in the metabolic effects of drugs, and recommendations for nutrition must be related to age, sex, reproductive status, and genetic endowment. Moreover, the illness being treated can itself alter nutritional requirements and the effect of the treatment on nutrient status. The changes in nutritional levels induced by use of estrogen-containing oral contraceptives (OCs) are obscure; however, the effects on folate matabolism appear to be of less clinical import than previously suggested. Reduction in pyridoxine and serum vitamin B12 levels has been reported among OC users, and requirements of thiamine and riboflavin may be increased. In cases where the therapy is justified, the nutritional consequences can often be justified. However, every effort should be made to identify nutritional side effects by proper assessment procedures and to manage them by oral or parenteral supplementation where feasible.^ieng
Asunto(s)
Enfermedad Iatrogénica , Trastornos Nutricionales/etiología , Animales , Anticonvulsivantes/efectos adversos , Antituberculosos/efectos adversos , Avitaminosis/etiología , Catárticos/efectos adversos , Clorpromazina/efectos adversos , Anticonceptivos Orales/efectos adversos , Diuréticos/efectos adversos , Antagonistas del Ácido Fólico , Humanos , Íleon/cirugía , Yeyuno/cirugía , Hepatopatías/etiología , Síndromes de Malabsorción/inducido químicamente , Síndromes de Malabsorción/etiología , Complicaciones Posoperatorias , Diálisis Renal , Estómago/cirugía , Estrés Fisiológico/complicacionesRESUMEN
The neuroleptic malignant syndrome is an uncommon, severe illness that consists of fever, muscular rigidity, and stupor. Various neuroleptics have been associated with the disease. A detailed neurological, medical, and neuropathological evaluation of this case was performed. Presumably, the syndrome is secondary to biochemical dysfunction of the basal ganglia and possible of the hypothalmus.